Masimo Co. (NASDAQ:MASI – Get Free Report) has been given an average recommendation of “Hold” by the seven analysts that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $117.14.
Several analysts recently issued reports on the company. Piper Sandler boosted their price target on Masimo from $70.00 to $117.00 and gave the company a “neutral” rating in a research note on Monday, February 26th. Needham & Company LLC downgraded Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Jefferies Financial Group reiterated a “hold” rating and set a $121.00 target price (up from $107.00) on shares of Masimo in a research report on Tuesday, January 30th. Wells Fargo & Company cut their target price on Masimo from $110.00 to $81.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 8th. Finally, StockNews.com upgraded Masimo from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th.
Check Out Our Latest Report on Masimo
Hedge Funds Weigh In On Masimo
Masimo Stock Up 0.1 %
NASDAQ:MASI opened at $129.67 on Thursday. The firm has a market capitalization of $6.86 billion, a price-to-earnings ratio of 85.87 and a beta of 0.95. Masimo has a twelve month low of $75.22 and a twelve month high of $198.00. The stock’s 50 day moving average price is $126.29 and its two-hundred day moving average price is $106.82. The company has a quick ratio of 1.22, a current ratio of 2.18 and a debt-to-equity ratio of 0.64.
Masimo (NASDAQ:MASI – Get Free Report) last issued its earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 EPS for the quarter, topping the consensus estimate of $0.82 by $0.43. The company had revenue of $548.90 million during the quarter, compared to the consensus estimate of $545.69 million. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.32 EPS. Equities research analysts expect that Masimo will post 3.53 earnings per share for the current fiscal year.
About Masimo
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.
Recommended Stories
- Five stocks we like better than Masimo
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- How to Use Options Collars to Hedge Your Stock Gains
- What is Insider Trading? What You Can Learn from Insider Trading
- Palantir Stock Spikes 6% on U.S. Army TITAN Contract
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- AeroVironment Stock Rockets To New High: Price Could Double Again
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.